Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: Evidence from the Symphony study

Nephrology Dialysis Transplantation

Volumn 27, Issue 2, 2012, Pages 850-857

  Claes, Kathleen ^a   Meier Kriesche, Herwig Ulf ^b   Schold, Jesse D ^c   Vanrenterghem, Yves ^a   Halloran, Philip F ^d   Ekberg, Henrik ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e University Hospital   (Sweden)

Author keywords

calcineurin inhibitor; metabolic parameters; renal transplantation; Symphony study

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CORTICOSTEROID; CYCLOSPORIN A; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; TRIACYLGLYCEROL; URIC ACID;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE COURSE; DRUG BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADRENAL CORTEX HORMONES; ADULT; BLOOD CHEMICAL ANALYSIS; BLOOD PRESSURE DETERMINATION; BODY MASS INDEX; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MYCOPHENOLIC ACID; PROGNOSIS; REFERENCE VALUES; RISK ASSESSMENT; SIROLIMUS; TACROLIMUS; TRANSPLANTATION IMMUNOLOGY;

EID: 84856882247     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr238     Document Type: Article

References (45)

1. Porrini E, Delgado P, Bigo C et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 2006; 48: 134-142
2. de Vries APJ, Bakker SJL, van Son WJ et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004; 4: 1675-1683
3. Ligtenberg G, Hene R, Blankestijn PJ et al. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001; 12: 368-373
4. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356: 194-202
5. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575
6. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-2497
7. Grundy SM, Brewer HB Jr., Cleeman JI et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438
8. Textor SC, Canzanello VJ, Taler SJ et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994; 69: 1182-1193
9. Singer DR, Jenkins GH. Hypertension in transplant recipients. J Hum Hypertens 1996; 10: 395-402
10. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741-746
11. Campos HH, Filho MA. One-year follow-up of a brazilian randomized multicenter study comparing tacrolimus versus cyclosporine in kidney transplantation. Transplant Proc 2002; 34: 1656-1658
12. Klein IH, Abrahams A, Van Ede T et al. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73: 732-736
13. Mayer AD, Dmitrewski J, Squifflet JP et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436-443
14. Pirsch JD, Miller J, Deierhoi MH et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977-983
15. Charpentier B, Rostaing L, Berthoux F et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003; 75: 844-851
16. Trompeter R, Filler G, Webb NJA et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002; 17: 141-149
17. Saudek F, Malaise J, Boucek P et al. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial. Nephrol Dial Transplant 2005; 20: ii3-ii10
18. Artz MA, Boots JMM, Ligtenberg G et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4: 937-945
19. Larson TS, Dean PG, Stegall MD et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514-522
20. Boots JM, van Duijnhoven EM, Christiaans MH et al. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002; 13: 221-227
21. Kasiske BL, Snyder JJ, Gilbertson D et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185
22. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16: 3128-3135
23. Roland M, Gatault P, Doute C et al. Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation. Transpl Int 2008; 25: 523-530
24. Johnston O, Rose CL, Webster AC et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411-1418
25. Groth CG, Bäckman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036-1042
26. Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine1. Transplantation 2002; 74: 1070-1076
27. Dmitrewski J, Krentz AJ, Mayer AD et al. Metabolic and hormonal effects of tacrolimus (FK506) or cyclosporin immunosuppression following renal transplantation. Diabetes Obes Metab 2001; 3: 287-292
28. Van Hooff J, Christiaans MHL, van Duijnhoven EM. Glucose metabolic disorder after transplantation. Am J Transplant 2007; 7: 1435-1436
29. Hoitsma AJ, Hilbrands LB. Relative risk of new-onset diabetes during the first year after renal transplantation in patients receiving tacrolimus or cyclosporine immunosuppression. Clin Transplant 2006; 20: 659-664
30. Vincenti F, Friman S, Scheuermann E et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506-1514
31. Filler G, Neuschulz I, Vollmer I et al. Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant 2000; 15: 867-871
32. Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834-841
33. Montori VM, Basu A, Erwin PJ et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002; 25: 583-592
34. Luan FL, Zhang H, Schaubel DE et al. Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. Am J Transplant 2008; 8: 1871-1877
35. Charpentier B. Bicetre hospital experience with sirolimus-based therapy in human renal transplantation: the sirolimus European renal transplant study. Transplant Proc 2003; 35: S58-S61
36. Morales JM, Wramner L, Kreis H et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436-442
37. Wissing KM, Unger P, Ghisdal L et al. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. Transplantation 2006; 82: 771-778
38. Chueh SJ, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003; 76: 375-382
39. Kreis H, Oberbauer R, Campistol JM et al. Long-Term Benefits with sirolimus-based therapy after Early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809-817
40. Gonwa T, Mendez R, Yang HC et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 2003; 75: 1213-1220
41. Morrisett JD, Abdel-Fattah G, Hoogeveen R et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43: 1170-1180
42. Sharif A, Ravindran V, Dunseath G et al. Comparison of rival metabolic syndrome classifications against pathophysiological markers in renal transplant recipients. Transplantation 2010; 89: 347-352
43. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89: 1-14
44. Van den Ham EC, Kooman JP, Christiaans MH et al. Weight changes after renal transplantation: a comparison between patients on 5-mg maintenance steroid therapy and those on steroid-free immunosuppressive therapy. Transpl Int 2003; 16: 300-306
45. Pascual J, van Hooff JP, Salmela K et al. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 2006; 82: 55-61